Immunosuppressive drug monitoring - What to use in clinical practice today to improve renal graft outcome

Transplant International

Volumn 18, Issue 2, 2005, Pages 140-150

  Kuypers, Dirk R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Calcineurin inhibitors; Immunosuppressive drug monitoring; Mammalian Target of Rapaurycin (mTOR) inhibitors; Mycophenolate mofetil; Renal transplantation; Therapeutic drug monitoring

Indexed keywords

ACYL GLUCURONIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GLUCURONIDE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; CALCINEURIN; CYCLOSPORIN; DRUG DERIVATIVE; MYCOPHENOLIC ACID; PROTEIN KINASE;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DRUG EXPOSURE; DRUG MONITORING; DRUG USE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; PHYSIOLOGY;

CALCINEURIN; CYCLOSPORINE; DRUG MONITORING; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PROTEIN KINASES; TACROLIMUS;

EID: 19544378313     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00041.x     Document Type: Review

References (131)

1. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin-inhibitor drugs: a prospective, randomised trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
2. Kahan BD. Sirolimus and FTY720: new approaches to transplant immunosuppression. Transplant Proc 2002; 34: 2520.
3. Margreiter R for the European Tacrolimus vs Ciclosporin-Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002; 359: 741.
4. van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 1934.
5. Kuypers DRJ, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of anti-CD25 monoclonal antibody and mycophenolate mofetil enables to use a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234.
6. Kuypers DRJ, Vanrenterghem Y. Tailoring immunosuppression. Nephrol Dial Transplant 2002; 17: 2051.
7. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539.
8. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589.
9. Evenepoel P, Vanrenterghem Y. Death with functioning graft - a preventable cause of graft loss. Ann Transplant 2001; 6: 17.
10. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
11. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70: SS58.
12. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889.
13. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
14. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555.
15. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74: 571.
16. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 2003; 42: 59.
17. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329.
18. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813.
19. Cox VC, Ensom HH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25: 137.
20. Milĺn O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003; 49: 1891.
21. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Naploi KL, Shaw LM. International federation of clinical chemistry/international association of therapeutic drug monitoring and clinical toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002; 24: 59.
22. Pou L, Brunet M, Bilbao I. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish study group: a two-year follow-up. Ther Drug Monit 1998; 20: 602.
23. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330.
24. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21: 35.
25. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
26. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide melabolite in adult kidney transplant recipients. Clin Pharm Ther 1999; 66: 492.
27. Kuypers DRJ, Vanrenlerghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide melabolites in renal allograft recipients on low dose lacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609.
28. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001; 23: 717.
29. Shipkova M, Scḧtz E, Armstrong VW, et al. Overestimation of mycophenolic acid by EMIT correlates with MPA melabolite. Transplant Proc 1999; 31: 1135.
30. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl-glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33: 107.
31. Nowak I, Wu J, Brayman KL, Shaw LM. Is the glucuronide metabolite of MPA pharmacologically active? Transplant Proc 1997; 29: 337.
32. Wong KM, Shek CC, Chau KF, Li CS. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000; 35: 660.
33. Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859.
34. Ku YM, Min DI. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit 1998; 20: 219.
35. Magali M-A, Charpiat B, Jelliffe RW, Ducerf C, Fourcade N, Baulieux J. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129.
36. Uchida K, Tominaga Y, Haba T, et al. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. Transplant Proc 1998; 30: 1276.
37. Cantarovich M, Fridell J, Barkun J, et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. Transplant Proc 1998; 30: 1460.
38. Undre NA, Stevenson PJ and the European Tacrolimus Heart Study Group. Pharmacokinetics of tacrolimus in heart transplantation. Transplant Proc 2002; 34: 1836.
39. Böttiger Y, Undre NA, Säwe J, Stevenson PJ, Ericzon BG. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc 2002; 34: 1544.
40. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503.
41. Shaefer MS, Collier DS, Haven MC, et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. Transplantation 1992; 56: 475.
42. Johnston A, Chusney G, Schütz E, Oellerich M, Lee TD, Holt DW. Monitoring cyclosporin in blood: between-assay differences at trough and 2-hours post-dose (C2). Ther Drug Monit 2003; 25: 167.
43. Kuzuya T, Ogura Y, Motegi Y, Moriyama N, Nabeshima T. Interference of hematocrit in the tacrolimus II micro-particle enzyme immunoassay. Ther Drug Monit 2002; 24: 507.
44. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for cellular rejection. Liver Transpl 2003; 9: 1159.
45. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24.
46. Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation 1996; 62: 1190.
47. Bekersky I, Dressler D., Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289.
48. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schäfer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998; 30: 1271.
49. Pisitkun T, Eiam-Ong S, Chusil S, Praditpornsilpa K, Pansin P, Tungsanga K. The roles of C4 and AUCO-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173.
50. 2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002; 17: 1487.
51. Stolk LML, Van Duijnhoven EM, Christiaans MHL, van Hooff JP. Through levels of tacrolimus. Ther Drug Monit 2002; 24: 573.
52. Willis C, Staatz CE, Tett SE. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit 2003; 25: 158.
53. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660.
54. Cremers SC, Scholten EM, Schoemaker RC. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003; 18: 1201.
55. Chen H, Chen T, Min DI, Fischer GW, Wu Y. Prediction of tacrolimus blood levels by using the neural network with genetic algorithm in liver transplantation patients. Ther Drug Monit 1999; 21: 50.
56. o-4 hduring the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc 2002; 34: 1736.
57. Potter JM. Pharmacoeconomics of therapeutic drug monitoring in transplantation. Ther Drug Monit 2000; 22: 36.
58. Morris RG, Lam AK. Cyclosporin monitoring in Australasia: survey of laboratory practices in 2000. Ther Drug Monit 2002; 24: 471.
59. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation 1996; 62: 900.
60. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 2001; 41: 542.
61. Undre NA, van Hooff JP, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296.
62. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920.
63. van Hooff JP, Boots JMM, van Duijnhoven E, Christiaans MHL. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc 1999; 31: 54S.
64. Claesson K, Mayer AD, Squifflet JP, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporin A patients. Transplant Proc 1998; 30: 1292.
65. Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporin to tacrolimus. Transplant Proc 1998; 30: 1240.
66. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporin. Transplantation 1998; 66: 1736.
67. Van Duijnhoven E, Christiaans M, Boots J, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporin-based immunosuppression. J Am Soc Nephrol 2002; 13: 213.
68. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434.
69. ss, rather than area under the curve, AUC. Ther Drug Monit 2003; 25: 743.
70. Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004; 43: 741.
71. van Duijnhoven E, Christiaans M, Schäfer A, Undre N, van Hooff J. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30: 1266.
72. Boots JMM, Christiaans MHL, Undre NA, van Hooff JP. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after transplantation? Transplant Proc 2002; 34: 3171.
73. Baran DA, Galin ID, Sandier D, et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. Transplant Proc 2002; 34: 1834.
74. Schmidt LE, Olsen AK, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther 2001; 70: 446.
75. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55.
76. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA. Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit 1998; 20: 276.
77. Charlebois JE, Lum BL, Cooney GF, Mochon M, Kaiser BA. Comparison and validation of limited sampling equations for cyclosporine area-under-the-curve monitoring calculations in pediatrie renal transplant recipients. Ther Drug Monit 1997; 19: 277.
78. Meier-Kriesche HU, Kaplan B, Brannan P, Kahan BD, Portman RJ. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. Ther Drug Monit 1998; 20: 401.
79. Marsh CL for the Neoral Study Group. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Ther Drug Monit 1999; 21: 27.
80. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001; 23: 100.
81. Mahalati K, Belitsky P, West K, et al. A 3-hour postdose cyclosporine level during the first week after kidney transplantation predicts acute rejection and cyclosporine nephrotoxicity more accurately than trough levels. Transplant Proc 2000; 32: 786.
82. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356.
83. Sindhi R, LaVia MF, Paulling E, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine + rapamycin regimen. Transplantation 2000; 69: 432.
84. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
85. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789.
86. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
87. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479.
88. Grant D, Kneteman N, Tchervenkov J, et al. Peak CsA levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomised comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation 1999; 67: 1133.
89. 2). Transplantation 2002; 73: 953.
90. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903.
91. 2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation 2003; 76: 1236.
92. 2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 2004; 19: 215.
93. Kaplan B, Wang Z, Abecassis M, Stuart FP, Kaufman DB. Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. Ther Drug Monit 1996; 18: 556.
94. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22: 169.
95. Schütz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. Transplant Proc 1998; 30: 1182.
96. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48: 1497.
97. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998, 38: 268.
98. MacPhee IAM, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000: 57: 1164.
99. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African Americans and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000, 40: 624.
100. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000, 22: 27.
101. Kaplan B, Meier-Kriesche HU, Friedman G, et al, The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999, 39: 715.
102. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998; 65: 1127.
103. Weber LT, Lamersdorf T, Shipkova M, et al. and Members of the German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit 1999, 21: 498.
104. Weber LT, Shipkova M, Lamersdorf T, et al. and Members of the German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998, 9: 1511.
105. Wieland E, Shipkova M, Weber L, et al. Mycophenolic acyl glucuronide plasma concentrations are higher in kidney transplant recipients suffering from diarrhoea and correlate with interleukin 6 release. Transplantation 2002; 74: 164.
106. Kuypers DRJ, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003; 43: 866.
107. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
108. Nanni G, Pisanti F, Navarra P, et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosuppression. Transplant Proc 2002; 34: 2085.
109. Mourad M, Malaise J, Chaib-Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47: 1241.
110. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143.
111. van Besouw NM, van der Mast BJ, Smak Gregoor PJH, et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999; 14: 2710.
112. RS-61443 Investigation Committee, Japan. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995; 27: 1421.
113. Holt DW, Denny K, Lee D, Johnston A. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. Transplant Proc 2003; 35: 157S.
114. Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22: B86.
115. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22: B101.
116. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573.
117. Kahan BD and The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet 2000; 256: 194.
118. Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations. Clin Ther 2000; 22: B93.
119. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97.
120. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346.
121. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients. Ther Drug Monit 2003; 25: 447.
122. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18: 12.
123. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69: 48.
124. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920.
125. Oberbauer R, Kreis H, Johnson R, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study. Transplantation 2003; 76: 364.
126. Smith KD, Wrenshall LE, Nicosia RF, et al Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycine use. J Am Soc Nephrol 2003; 14: 1037.
127. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416.
128. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999: 67: 1036.
129. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.
130. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75: 157.
131. Kaplan B, Meier-Kriesche HU, Napoli K, Kahan BD. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Clin Chem 1997; 43: 539.